text.skipToContent text.skipToNavigation

{{ addToCartData.mixPtRmWarning }}

您是否要继续?

{{requestQuote.productName}}; {{requestQuote.form.productCode}}

谢谢

我们将很快回复您的问询。

Something went wrong, please try again later.

大宗订单
如不确定,请点击“取消”。您也可保存此商品,稍后再作决定。
取消
如不确定,请点击“取消”。您也可保存此商品,稍后再作决定。
取消

Imatinib

Price and availability

48-hour USA dispatch time
{{ psProduct.packSize }}
{{ psProduct.code }}

{{ favouriteItem.successMessage }}

查看收藏夹

产品已从收藏夹中删除

{{ addToCartData.mixPtRmWarning }}

您是否要继续?

{{requestQuote.productName}}; {{requestQuote.form.productCode}}

谢谢

我们将很快回复您的问询。

Something went wrong, please try again later.

证明文件

我们应该把您请求的CoA寄到哪里?
产品编号:  {{ coaPopupData.packSize.code }}

{{ errors.first('lotNumber') }}

{{ errors.first('requestEmail') }}

LGC将仅在提供您所需文件时使用您的电子邮件地址。
如需了解有关我们数据处理活动的信息,请访问我们的《隐私声明》
我们应该把您请求的CoA寄到哪里?

请输入您的电子邮件地址,我们将通过电子邮件向您发送批次的相关CoA:
{{ coaPopupData.packSize.coaSelectedLotNumbers }}

{{ errors.first('coaEmail') }}

输入您的电子邮件地址则代表您确认同意LGC不时向您分享与上述产品和其他类似产品有关的信息。 LGC将根据所有适用的数据保护规则和条例处理您的个人数据。有关LGC数据处理的信息,请访问下方的《隐私政策》(见页脚)。
谢谢

我们会将CoA发送到您的电子邮件地址  {{ coaEmailPopupData.userEmail }}

谢谢

您的请求已发送给我们的销售团队处理。

产品信息

产品说明

Imatinib is a 2-phenyl amino pyrimidine derivative that functions as a tyrosine kinase inhibitor, including the Bcr-AbI pathway. It is an orally bioactive anti-cancer agent used in the treatment of cancers such as chronic myelogenous leukaemia (CML) and acute lymphocytic leukaemia (ALL), all of which are Philadelphia chromosome-positive (Ph+), as well as hypereosinophilic syndrome (HES) and certain types of gastrointestinal stromal tumours (GIST).  
References
[1] Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Education Program Book; 50th ASH Conference; 2008. pp. 419–426.
[2] Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996. 1996;2:561–566. doi: 10.1038/nm0596-561.
[3] Deininger MW, Druker BJ: Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev. 2003 Sep;55(3):401-23. Epub 2003 Jul 1.
[4] Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL: Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006 Jul 15;107(2):345-51.

Chemical Data

分析物名称

Imatinib

CAS登记号

152459-95-5

分子式

C29 H31 N7 O

分子量

493.60

精确质量测定

493.259

SMILES

CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1

InChI

InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)

IUPAC

4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide

备用CAS登记号

Labelled: 1092942-82-9

产品数据

存储温度

-20°C

运输温度

Room Temperature

原产国

CANADA

产品类型

API

产品形式

Neat

HPLC Purity

>95%

Punchout session timeout warning

Your punchout session will expire in1 min59 sec.

Select "Continue session" to extend your session.